AFF3 and breast neoplasm: Finally, patients with ER+ (luminal A/B) primary breast tumors with AFF3 upregulation had significantly worse outcome, in comparison with patients whose primary breast tumors did not upregulate AFF3. Our results suggest that the latter may have de novo resistance to tamoxifen and perhaps to other endocrine therapies.